NurExone Welcomes Jacob Licht A Biopharmaceutical Veteran To Oversee U.S. Operations And Exo-Top Expansion

NurExone Biologic Inc., a preclinical-stage biotechnology company pioneering regenerative exosome-based therapies for central nervous system (CNS) injuries, today announced the appointment of Jacob Licht as Chief Executive Officer of Exo-Top Inc., a wholly owned U.S. subsidiary, and as Vice President, Corporate Development at NurExone. Exo-Top is a GMP-compliant manufacturing facility in the U.S. and is positioned as a cornerstone in NurExone’s global supply chain and commercialization efforts.

“Jacob’s appointment underscores our commitment to operational excellence and financial growth in the U.S. market,” said Dr. Lior Shaltiel, Chief Executive Officer of NurExone. “Exo-Top is expected to be integral to scaling our manufacturing capacity, building robust quality systems, and supporting our progress towards human clinical trials and commercialization.”

Yoram Drucker, Chairman of NurExone, “Exo-Top will serve as the cornerstone of our exosome production in the U.S., and Jacob is the right executive to lead it. His track record in scaling biotech operations, executing transformative deals, and his business acumen aligns perfectly with our financial strategy as we scale to grow revenue and expand our North America footprint.”

“NurExone’s platform has the potential to transform how we treat Central Nerve Injuries in multiple indications. The leadership team is exceptional, and with Exo-Top, we’re building the infrastructure to support global production, operational independence, and long-term value creation”, commented Jacob Licht.

Jacob Licht brings over 20 years of experience in biotech and specialty pharmaceuticals, having led transactions totaling $1 billion across M&A, licensing, and asset sales. His previous leadership roles include positions at Lantheus Medical Imaging, Bavarian Nordic, and Emergent BioSolutions. In addition, NurExone announced that it has completed its continuance from the Province of Alberta to the Province of Ontario, effective April 22, 2025. The continuance was approved by shareholders during the company’s annual general and special meeting held on June 3, 2024.